Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II‐III)
S. D. Shafran; D. Shaw; M. Charafeddine; K. Agarwal; G. R. Foster; M. Abunimeh; T. Pilot‐Matias; R. K. Pothacamury; B. Fu; E. Cohen; D. E. Cohen; E. Gane
Author Information: Division of Infectious Diseases, Department of Medicine
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.